JP7856264B2 - Ｓａｐ ｆｃ融合タンパク質及び使用方法 - Google Patents

Ｓａｐ ｆｃ融合タンパク質及び使用方法

Info

Publication number
JP7856264B2
JP7856264B2 JP2023526513A JP2023526513A JP7856264B2 JP 7856264 B2 JP7856264 B2 JP 7856264B2 JP 2023526513 A JP2023526513 A JP 2023526513A JP 2023526513 A JP2023526513 A JP 2023526513A JP 7856264 B2 JP7856264 B2 JP 7856264B2
Authority
JP
Japan
Prior art keywords
sap
fusion protein
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023526513A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550287A5 (enExample
JP2023550287A (ja
Inventor
ジョーム・ポンズ
ジョナサン・エス・ウォール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of JP2023550287A publication Critical patent/JP2023550287A/ja
Publication of JP2023550287A5 publication Critical patent/JP2023550287A5/ja
Application granted granted Critical
Publication of JP7856264B2 publication Critical patent/JP7856264B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023526513A 2020-11-02 2021-11-01 Ｓａｐ ｆｃ融合タンパク質及び使用方法 Active JP7856264B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063108799P 2020-11-02 2020-11-02
US63/108,799 2020-11-02
US202163153777P 2021-02-25 2021-02-25
US63/153,777 2021-02-25
PCT/US2021/072168 WO2022094630A1 (en) 2020-11-02 2021-11-01 Sap fc fusion proteins and methods of use

Publications (3)

Publication Number Publication Date
JP2023550287A JP2023550287A (ja) 2023-12-01
JP2023550287A5 JP2023550287A5 (enExample) 2024-11-11
JP7856264B2 true JP7856264B2 (ja) 2026-05-11

Family

ID=78771272

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526513A Active JP7856264B2 (ja) 2020-11-02 2021-11-01 Ｓａｐ ｆｃ融合タンパク質及び使用方法

Country Status (10)

Country Link
US (2) US12161692B2 (enExample)
EP (1) EP4237083A1 (enExample)
JP (1) JP7856264B2 (enExample)
KR (1) KR20230097061A (enExample)
AU (1) AU2021368272A1 (enExample)
BR (1) BR112023008317A2 (enExample)
CA (1) CA3196766A1 (enExample)
IL (1) IL302388A (enExample)
MX (1) MX2023005063A (enExample)
WO (1) WO2022094630A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
BR112023008317A2 (pt) 2020-11-02 2024-02-06 Attralus Inc Proteínas de fusão sap fc e métodos de uso
WO2024153768A1 (en) * 2023-01-20 2024-07-25 Boehringer Ingelheim International Gmbh Il-12 fc fusion proteins

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530714A (ja) 2009-06-17 2012-12-06 プロメディオール， インコーポレイテッド Ｓａｐ変異体及びその使用
JP2015502373A (ja) 2011-12-19 2015-01-22 シンイミューン ゲーエムベーハー 二重特異性抗体分子
US20180298071A1 (en) 2013-10-31 2018-10-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Chimeric Protein in the Treatment of Amyloidosis
WO2019197651A1 (en) 2018-04-12 2019-10-17 Mediapharma S.R.L. Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
JP2020521458A (ja) 2017-05-25 2020-07-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317120D0 (en) 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
AU2002225772A1 (en) 2000-11-27 2002-06-03 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
US9200079B2 (en) * 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
WO2011119608A1 (en) 2010-03-26 2011-09-29 University Of Tennessee Research Foundation Peptides that specifically target amyloid deposits
WO2013096847A1 (en) 2011-12-21 2013-06-27 Promedior, Inc. Serum amyloid p-antibody fusion proteins
EP3027647A4 (en) 2013-07-31 2017-01-04 Amgen Inc. Stabilization of fc-containing polypeptides
US9683017B2 (en) 2014-07-17 2017-06-20 University Tennessee Research Foundation Inhibitory peptides of viral infection
US10213506B2 (en) 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
BR112023008317A2 (pt) 2020-11-02 2024-02-06 Attralus Inc Proteínas de fusão sap fc e métodos de uso

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530714A (ja) 2009-06-17 2012-12-06 プロメディオール， インコーポレイテッド Ｓａｐ変異体及びその使用
JP2015502373A (ja) 2011-12-19 2015-01-22 シンイミューン ゲーエムベーハー 二重特異性抗体分子
US20180298071A1 (en) 2013-10-31 2018-10-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Chimeric Protein in the Treatment of Amyloidosis
JP2020521458A (ja) 2017-05-25 2020-07-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物
WO2019197651A1 (en) 2018-04-12 2019-10-17 Mediapharma S.R.L. Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JBC，2001年，Vol.276,No.9，p.6591-6604

Also Published As

Publication number Publication date
US20220160831A1 (en) 2022-05-26
WO2022094630A1 (en) 2022-05-05
US20250152667A1 (en) 2025-05-15
CA3196766A1 (en) 2022-05-05
AU2021368272A1 (en) 2023-06-08
MX2023005063A (es) 2023-05-12
KR20230097061A (ko) 2023-06-30
IL302388A (en) 2023-06-01
US12161692B2 (en) 2024-12-10
JP2023550287A (ja) 2023-12-01
BR112023008317A2 (pt) 2024-02-06
AU2021368272A9 (en) 2025-03-13
EP4237083A1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
US20250152667A1 (en) Sap fc fusion proteins and methods of use
US10213506B2 (en) Targeting immunotherapy for amyloidosis
US11919947B2 (en) Antibody binding active α-synuclein
JP7458327B2 (ja) 血液脳関門移動化合物及びその使用
CA2891190C (en) Aprotinin-derived polypeptide-antibody conjugates
US20230002460A1 (en) Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
WO2025242094A1 (zh) 靶向bdca2的抗体或其抗原结合片段及其应用
US20240082354A1 (en) Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
CN117120479A (zh) Sap fc融合蛋白及其使用方法
EA049439B1 (ru) СЛИТЫЕ БЕЛКИ SAP-Fc И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CA2860304A1 (en) Serum amyloid p-antibody fusion proteins
RU2836280C1 (ru) Слитый белок gdf15 длительного действия и содержащая его фармацевтическая композиция
WO2025070337A1 (ja) 抗ＭｅｒＴＫアゴニスト抗体、抗ＭｅｒＴＫ二重特異性抗体、及びその使用
HK40073215A (en) Long-acting gdf15 fusion protein and pharmaceutical composition comprising same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241031

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260415

R150 Certificate of patent or registration of utility model

Ref document number: 7856264

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150